Literature DB >> 21159857

Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition.

Christine J Pol1, Alice Muller, Marian J Zuidwijk, Elza D van Deel, Ellen Kaptein, Alessandro Saba, Maja Marchini, Riccardo Zucchi, Theo J Visser, Walter J Paulus, Dirk J Duncker, Warner S Simonides.   

Abstract

Similarities in cardiac gene expression in hypothyroidism and left ventricular (LV) pathological remodeling after myocardial infarction (MI) suggest a role for impaired cardiac thyroid hormone (TH) signaling in the development of heart failure. Increased ventricular activity of the TH-degrading enzyme type 3 deiodinase (D3) is recognized as a potential cause. In the present study, we investigated the cardiac expression and activity of D3 over an 8-wk period after MI in C57Bl/6J mice. Pathological remodeling of the noninfarcted part of the LV was evident from cardiomyocyte hypertrophy, interstitial fibrosis, and impairment of contractility. These changes were maximal and stable from the first week onward, as was the degree of LV dilation. A strong induction of D3 activity was found, which was similarly stable for the period examined. Plasma T(4) levels were transiently decreased at 1 wk after MI, but T(3) levels remained normal. The high D3 activity was associated with increased D3 mRNA expression at 1 but not at 4 and 8 wk after MI. Immunohistochemistry localized D3 protein to cardiomyocytes. In vivo measurement of TH-dependent transcription activity in cardiomyocytes using a luciferase reporter assay indicated a 48% decrease in post-MI mice relative to sham-operated animals, and this was associated with a 50% decrease in LV tissue T(3) concentration. In conclusion, pathological ventricular remodeling after MI in the mouse leads to high and stable induction of D3 activity in cardiomyocytes and a local hypothyroid condition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159857     DOI: 10.1210/en.2010-0431

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  45 in total

1.  Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice.

Authors:  Cintia B Ueta; Behzad N Oskouei; Emerson L Olivares; Jose R Pinto; Mayrin M Correa; Gordana Simovic; Warner S Simonides; Joshua M Hare; Antonio C Bianco
Journal:  Mol Endocrinol       Date:  2012-03-08

2.  Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings.

Authors:  Iordanis Mourouzis; Polixeni Mantzouratou; Georgios Galanopoulos; Erietta Kostakou; Nikolaos Roukounakis; Alexandros D Kokkinos; Dennis V Cokkinos; Constantinos Pantos
Journal:  Mol Cell Biochem       Date:  2011-12-02       Impact factor: 3.396

Review 3.  Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.

Authors:  Mark R Heckle; David M Flatt; Yao Sun; Salvatore Mancarella; Tony N Marion; Ivan C Gerling; Karl T Weber
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

Review 4.  Misinterpretation of the mouse ECG: 'musing the waves of Mus musculus'.

Authors:  Bastiaan J Boukens; Mathilde R Rivaud; Stacey Rentschler; Ruben Coronel
Journal:  J Physiol       Date:  2014-09-25       Impact factor: 5.182

Review 5.  Role of thyroid hormones in ventricular remodeling.

Authors:  Viswanathan Rajagopalan; A Martin Gerdes
Journal:  Curr Heart Fail Rep       Date:  2015-04

Review 6.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

7.  Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy.

Authors:  Ari J Wassner; Rebecca H Jugo; David M Dorfman; Robert F Padera; Michelle A Maynard; Ann M Zavacki; Patrick Y Jay; Stephen A Huang
Journal:  Thyroid       Date:  2017-04-05       Impact factor: 6.568

8.  N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial.

Authors:  Josi Vidart; Simone Magagnin Wajner; Rogério Sarmento Leite; André Manica; Beatriz D Schaan; P Reed Larsen; Ana Luiza Maia
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

9.  Long-term physiological T3 supplementation in hypertensive heart disease in rats.

Authors:  Nathan Y Weltman; Christine J Pol; Youhua Zhang; Yibo Wang; Adrienne Koder; Sarah Raza; Riccardo Zucchi; Alessandro Saba; Daria Colligiani; A Martin Gerdes
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

10.  Low-dose T₃ replacement restores depressed cardiac T₃ levels, preserves coronary microvasculature and attenuates cardiac dysfunction in experimental diabetes mellitus.

Authors:  Nathan Y Weltman; Kaie Ojamaa; Evelyn H Schlenker; Yue-Feng Chen; Riccardo Zucchi; Alessandro Saba; Daria Colligiani; Viswanathan Rajagopalan; Christine J Pol; A Martin Gerdes
Journal:  Mol Med       Date:  2014-05-01       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.